amitifadine
Amitifadine is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) or so-called triple reuptake inhibitor (TRI) which is or was being developed by Euthymics Bioscience. It was under development for the treatment of major depressive disorder, but in May 2013, it was reported that the drug failed to show superior efficacy to placebo in a phase IIb/IIIa clinical trial. it was suggested that this may have been due to the drug being underdosed. In September 2017, development of amitifadine for the treatment of major depressive disorder was finally officially discontinued. As of September 2017, it is still listed as being under development for the treatment of alcoholism and smoking withdrawal. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2008 (NCT00659347)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
- Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Chemistry & pharmacology
SMILES
Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl- Mol. weight
- 228.12 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL592374 ↗
- WikipediaAmitifadine ↗
Also known as
- 1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride
- amitifadine
- dov 216303
- dov 216,303
- dov21947
- dov 21947
- dov 21,947
- dov 21,947
- dov 21,947
- dov-21947
- eb-1010
- eb-1010
- eb-1010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01318434 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2011 | Euthymics BioScience, Inc. |
| NCT00659347 | Phase 2 | Mar 1, 2008 | DOV Pharmaceutical, Inc. |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DOV Pharmaceutical, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Euthymics BioScience, Inc. | For profit | 1 | 1 | 1 | 2011 |